New Stock News | Rui Touch Siasun Robot & Automation plans Hong Kong IPO. The China Securities Regulatory Commission requires an explanation of the tax payment situation for the transfer of ownership in the transfer segment.

On May 29th, the China Securities Regulatory Commission (CSRC) announced the supplementary materials requirements for overseas issuance and listing approval (May 25, 2026 to May 29, 2026). The CSRC requested Siasun Robot & Automation to further explain the significant differences between the pricing of the transfer of shares by new shareholders within the 12 months prior to submitting the application for overseas issuance and listing approval, and the rationale for such differences, as well as to provide clear evidence. They also requested information on the tax payments made by the transferors in the share transfer process. According to the Hong Kong Stock Exchange's disclosure on May 27th, Siasun Robot & Automation submitted its listing application to the main board of the Hong Kong Stock Exchange, with EB SECURITIES International as the sole sponsor. At the same time, the CSRC requested Siasun Robot & Automation to explain whether the business scope and actual operations of the issuer and its subsidiaries are subject to the "Special Management Measures for Foreign Investment Market Access (Negative List) (2024 Edition)" in terms of prohibited or restricted areas for foreign investment. They also asked for an explanation of whether the shares held by the shareholders participating in the "full circulation" in this offering are subject to pledges, freezes, or other defects. According to information from Zhoushi Consultancy, Siasun Robot & Automation is a pioneer and leading enterprise in the Chinese percutaneous surgery market. In 2024, the RC120 percutaneous surgery navigation system ranked second in the Chinese percutaneous surgery market based on trial installations. The prospectus shows that Siasun Robot & Automation was established in 2019 and is primarily engaged in the research and development, production, and commercialization of percutaneous surgery robotics. The company started clinical trials of the RC120 percutaneous surgery robot on January 7, 2022, and completed them on February 20, 2023. In 2024, the company obtained a Class III medical device registration certificate for the RC120 percutaneous surgery robot. As of November 25, 2025, the company has successfully commercialized the RC120 percutaneous surgery robot.